Skip to main content

Table 3 Summary of C-KIT Trials

From: Therapy for metastatic melanoma: the past, present, and future

Trial

Patients

RR%

(CR/PR)

PFS

(month)

OS

Number

(patients)

Summary

Single Arm Phase 2

Kim KB et al. [52]

Imatinib mesylate 400 mg bid in advanced unresectable melanoma

5%

1.4

7.5 months

21

Imatinib mesylate demonstrated a response in 1 patient who also had high c-kit expression and alternate splicing variant in c-kit mRNA transcript.

Single Arm Phase 2

Carvajal et al. [54]

Imatinib mesylate 400 mg bid in advanced unresectable melanoma

16%

3

46.3

weeks

28

Imatinib mesylate demonstrated a significant clinical response in subset of patients with cKit mutation and advanced melanomaa

Single Arm Phase 2

Guo et al. [53]

Imatinib mesylate 400 mg daily in metastatic melanoma

23.3%

3.5

14

months

43

Imatinib mesylate demonstrated a significant clinical response in a subset of patients with cKit mutation and metastatic melanomaa

  1. athe clustering of responses in both trials were seen in patients harboring c-kit mutations at exon 11 or exon 13; c-kit overexpression on IHC without a mutation did not correlate with a response. CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response; RR, response rate.